Related Experiment Videos
Low-molecular-weight heparin: more indications for use
1Department of Medicine, Oregon Health Sciences University School of Medicine, Portland, USA.
Hospital Practice (1995)
|April 23, 1999
Summary
Low-molecular-weight heparin can treat deep-vein thrombosis in more patients, including those who are pregnant or have pulmonary embolism. Careful patient selection and monitoring enable safe outpatient treatment for these individuals.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Initial low-molecular-weight heparin (LMWH) studies for deep-vein thrombosis (DVT) excluded specific patient groups.
- Exclusion criteria included pregnant women, patients with acute pulmonary embolism (PE), and those with hypercoagulable disorders.
Observation:
- These previously excluded conditions are not absolute contraindications for LMWH treatment.
- Outpatient management of DVT with LMWH is feasible in a broader patient population.
Findings:
- Proper patient selection and diligent follow-up are crucial for safe and effective LMWH therapy.
- LMWH can be safely administered to patients with DVT who have previously been excluded from trials.
Implications:
- Expanded use of LMWH for DVT treatment can improve patient access to care.
- Outpatient DVT management with LMWH may reduce healthcare costs and improve patient convenience.
- Further research should focus on optimizing LMWH protocols for these expanded patient groups.